CTMX Stock Analysis: CytomX Therapeutics | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 466m USD | 12M Return: -52.7% | US23284F1057 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 9.53M
Qual. Beats: 0
Rev. Trend: -60.8%
Qual. Beats: -1
Warnings
Tailwinds
No distinct edge detected
Seasonality 11.1 years of data, until 10/2026
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, ≥40 worth a closer look and ≥60 is strong.
CytomX Therapeutics is an oncology-focused biopharmaceutical company that develops conditionally activated biologics designed to act within the tumor microenvironment. The company leverages its proprietary Probody platform, which masks therapeutic activity until the drug is activated by tumor-associated proteases, a mechanism intended to widen the therapeutic window and reduce off-target effects. This conditional activation approach distinguishes CytomX within the broader class of antibody-drug conjugates (ADCs) and T-cell engagers (TCEs), where improving tolerability remains a central development hurdle.
The pipeline spans multiple modalities, including CX-904, a T-cell engaging bispecific antibody targeting EGFR on tumor cells and CD3 on T cells; CX-2051, a conditionally activated ADC directed at EpCAM-expressing epithelial cancers such as colorectal cancer; and CX-801, an interferon alpha-2b Probody cytokine being evaluated in combination with Mercks KEYTRUDA (pembrolizumab) under a clinical trial collaboration and supply agreement. Additional candidates include CX-2029, a conditional ADC targeting CD71, and BMS-986288, a Probody version of non-fucosylated ipilimumab developed with Bristol Myers Squibb.
CytomX pursues a partnership-driven business model, maintaining strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna, which is a common structure for clinical-stage biotech firms that rely on larger pharmaceutical partners for late-stage development and commercialization. Founded in 2008 and headquartered in South San Francisco, California, the company went public in October 2015 and operates within the biotechnology sub-industry of the healthcare sector.
- CX-904 and CX-2051 clinical data readouts drive valuation
- Partnership milestones from BMS and Astellas support collaboration revenue
- Cash burn raises dilution risk amid ongoing pipeline development
| Net Income: -79.7m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.22 > 0.02 and ΔFCF/TA 22.74 > 1.0 |
| NWC/Revenue: 1.82k% < 20% (prev 88.87%; Δ 1.73k% < -1%) |
| CFO/TA -0.22 > 3% & CFO -82.4m > Net Income -79.7m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 9.36 > 1.5 & < 3 |
| Outstanding Shares: last quarter (218.9m) vs 12m ago 69.62% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 6.58% > 50% (prev 80.60%; Δ -74.02% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM) |
| A: 0.87 (Total Current Assets 373.2m - Total Current Liabilities 39.9m) / Total Assets 381.2m |
| B: -1.97 (Retained Earnings -750.9m / Total Assets 381.2m) |
| C: -0.29 (EBIT TTM -79.4m / Avg Total Assets 278.1m) |
| D: 3.82 (Book Value of Equity 302.1m / Total Liabilities 79.2m) |
| Altman-Z'' = 1.40 = BB |
| DSRI: 3.0 (Receivables 37.5m/1.87m, Revenue 18.3m/141.1m) |
| GMI: 1.00 (GM 98.75% / 98.63%) |
| AQI: 0.35 (AQ_t 0.01 / AQ_t-1 0.01) |
| SGI: 0.13 (Revenue 18.3m / 141.1m) |
| TATA: 0.01 (NI -79.7m - CFO -82.4m) / TA 381.2m) |
| Beneish M = -2.39 (Cap -4..+1) = BBB |
As of November 11, 2026, the stock is trading at USD 1.98 with a total of 16,649,758 shares traded. Over the past week, the price has changed by -9.17%, over one month by -18.18%, over three months by -42.44% and over the past year by -52.74%.
Current recommended Stop Loss: 1.70 (which is 14.1% or 1.6 ATR below the current price).
CytomX Therapeutics has received a consensus analysts rating of 4.63. Therefore, it is recommended to buy CTMX.
- StrongBuy: 5
- Buy: 3
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 12.3 | 518.7% |
P/E Forward = 14.2045
P/S = 33.241
P/B = 1.6952
P/EG = -1.8
Revenue TTM = 18.3m USD
EBIT TTM = -79.4m USD
EBITDA TTM = -78.5m USD
Long Term Debt = 4.21m USD (estimated: total debt 5.70m - short term 1.50m)
Short Term Debt = 1.50m USD (from shortTermDebt, last quarter)
Debt = 5.70m USD (from shortLongTermDebtTotal, last quarter) (leases 5.70m already included)
Net Debt = -324.6m USD (calculated: Debt 5.70m - CCE 330.3m)
Enterprise Value = 141.7m USD (466.3m + Debt 5.70m - CCE 330.3m)
Interest Coverage Ratio = unknown (Ebit TTM -79.4m / Interest Expense TTM 0.0)
EV/FCF = -1.72x (Enterprise Value 141.7m / FCF TTM -82.5m)
FCF Yield = -58.20% (FCF TTM -82.5m / Enterprise Value 141.7m)
FCF Margin = -450.7% (FCF TTM -82.5m / Revenue TTM 18.3m)
Net Margin = -435.2% (Net Income TTM -79.7m / Revenue TTM 18.3m)
Gross Margin = unknown ((Revenue TTM 18.3m - Cost of Revenue TTM 251k) / Revenue TTM)
Tobins Q-Ratio = 0.37 (Enterprise Value 141.7m / Total Assets 381.2m)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 5.70m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -62.7m (EBIT -79.4m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 9.36 (Total Current Assets 373.2m / Total Current Liabilities 39.9m)
Debt / Equity = 0.02 (Debt 5.70m / totalStockholderEquity, last quarter 302.1m)
Debt / EBITDA = 4.14 (negative EBITDA) (Net Debt -324.6m / EBITDA -78.5m)
Debt / FCF = 3.94 (negative FCF - burning cash) (Net Debt -324.6m / FCF TTM -82.5m)
Total Stockholder Equity = 207.1m (last 4 quarters mean from totalStockholderEquity)
RoA = -28.64% (Net Income -79.7m / Total Assets 381.2m)
RoE = -38.46% (Net Income TTM -79.7m / Total Stockholder Equity 207.1m)
RoCE = -37.59% (EBIT -79.4m / Capital Employed (Equity 207.1m + L.T.Debt 4.21m))
RoIC = -18.35% (negative operating profit) (NOPAT -62.7m / Invested Capital 341.9m)
WACC = 17.54% (E(466.3m)/V(472.0m) * Re(17.75%) + D(5.70m)/V(472.0m) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 17.75% (= CAPM, Blume Beta Adj.) -> capped to 12.54%
Shares (quarterly) Correlation: 93.07 | Cagr: 54.20%
[DCF] Fair Price = unknown (Cash Flow -82.5m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.0 | # QB: 0
Revenue Correlation: -60.76 | Revenue CAGR: -34.72% | SUE: -1.03 | # QB: -1
EPS current Year (2026-12-31): EPS=-0.39 | Chg30d=+0.36% | Revisions=+25% | GrowthEPS=-159.2% | GrowthRev=-67.2%
EPS next Year (2027-12-31): EPS=-0.47 | Chg30d=+0.61% | Revisions=+25% | GrowthEPS=-21.0% | GrowthRev=+1.2%
[Analyst] Revisions Ratio: +40% (up=2, down=0)